Biomea Fusion reports weight loss data from oral GLP-1 trial

Biomea Fusion (BMEA) reported that BMF-650, its GLP-1 drug, showed up to 6.1% weight loss in early trials. The company cautioned about interpreting results due to placebo effects. BMF-650 was generally well-tolerated, with mild to moderate side effects. Biomea plans further studies and seeks partnerships for Phase II development, focusing on obesity and diabetes.

Biomea Fusion reported Phase 1 data for BMF-650, showing 1.5%–3.2% weight loss at Day 29 in outpatient cohorts vs 0.1% placebo, and 6.1% in a confined cohort with rapid titration. No severe adverse events were reported. The company will host a conference call on October 13.

Biomea Fusion (BMEA) reported Phase 1 trial results for BMF-650, an oral weight-loss drug. The study showed 1.5% to 3.2% weight reduction in four weeks, with good tolerability. The company plans further evaluation and potential partnerships. A conference call is scheduled for October 13, 2026.

Biomea Fusion (BMEA) shares rose 6.44% to $1.44 premarket ahead of Phase I data release for obesity drug BMF-650. The trial evaluates safety, tolerability, and weight reduction in overweight/obese participants. The company expects cash runway into Q2 2027. BMEA has traded between $0.87 and $2.23 in the past year.

Brookline Capital initiated coverage on Biomea Fusion (BMEA) with a Buy rating and $10 target, citing undervaluation and strong balance sheet. The company is developing icovamenib for diabetes and BMF-650 for obesity. Two Phase 2 trials for icovamenib in type 2 diabetes are ongoing, with topline results expected in Q1 2027. H.C. Wainwright and Citizens also reiterated Buy ratings with $4 and $7 targets, respectively. Biomea canceled a planned public offering due to unfavorable market conditions.

Biomea Fusion (BMEA) canceled its planned securities offering, citing unfavorable market conditions. The company's shares are down 17.35% to $1.40. BMEA's stock has ranged from $0.87 to $2.99 over the past year.